North America Neurological Biomarkers Market Developments and Forecast by 2027

The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019. The market is estimated to grow with a CAGR of 13.4% from 2020-2027.

Biomarkers are the molecules that indicate about the presence of a disease. The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology have enabled to track the health condition of the brain by measuring the biomarkers. This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.

Neurological diseases contribute to a significant burden on health systems in terms of disease diagnosis, treatment, and management. Some of the major neurological disorders are epilepsy, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others. As per the data published by the National Institutes of Neurological Disorders and Stroke in 2019, around 7,000 rare neurological diseases have been registered in the US. Additionally, according to the same study, these conditions are responsible for a significant number of morbidity and mortality. As per the 2019 Alzheimer’s disease Facts and Figures Report, in the year 2019, there were 5.8 million Americans of all ages were suffering from Alzheimer’s dementia. Among 5.8 million patients, 81% of the patients were aged 75 years and above. According to the Global Burden Disease (GBD) 2017, and Disease and Injury Incidence and Prevalence report, 20 million people across the globe suffer from Schizophrenia. Additionally, as per the Bio News Services, LLC, seven to ten million people across the globe suffer from Parkinson’s disease.Thus, increasing prevalence of neurological diseases is a major factor driving the growth of the North America neurological biomarker market during the forecast period.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak. This has eventually shifted their focus from development of new neurological biomarkers to vaccine development for COVID-19. Moreover, diversion of resources from neurological biomarkers development to COVID-19 treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, pharmaceutical supplies and procurement are also badly affected by the outbreak of COVID-19 in North America.

Mexico Neurological Biomarkers Market Revenue and Forecasts to 2027 (US$ Million)

NORTH AMERICANEUROLOGICAL BIOMARKERS MARKET SEGMENTATION

By Product

• Proteomics Biomarker
• Genomics Biomarker
• Metabolomics Biomarker
• Imaging Biomarker
• Others

By Application

• Alzheimer’s Disease
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Spinal Muscular Atrophy
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostics
• Research Organizations

By Country

• US
• Canada
• Mexico

Companies Mentioned

• Thermo Fisher Scientific, Inc
• Bio-Rad Laboratories Inc.
• Banyan Biomarkers
• Abbott
• Quest Diagnostics Incorporated
• Perkin Elmer, Inc.

North America Neurological Biomarkers Report Scope